logo
As Canada's income gap widens, some of those who are struggling sort trash to survive

As Canada's income gap widens, some of those who are struggling sort trash to survive

Yahoo11-08-2025
Grant Kilian likes to move fast between the tall blue recycling bins he sorts through, in Vancouver's West End alleys.
Time, but more accurately, cans are money here. The faster you can fill a bag, the faster you can get paid at the return depot. A big garbage bag full of beer cans, some of which he says he crushes, at 10 cents a pop, could earn Kilian about $30 in tax-free cash.
As he puts it, it's just a bit of extra money for food, bills or cigarettes when everything feels tight.
"I don't do crime or steal, so it's just an honest way of making some extra money, and I'm pretty good at it. I can make $50-$60 in a couple of hours", he said.
Kilian is a "binner." It's a word you won't find in most dictionaries, but it bluntly describes "a person who collects redeemable containers and other things from bins to sustain their livelihood and to divert waste from landfills," according to the definition at the Binners Project. The group, which advocates for binners in B.C., says there are more people than ever collecting things from trash cans for money in Vancouver, especially compared to past summers.
Unsurprisingly, warmer months are the best times to find dozens of empty beer, soda and other drink containers in the city. Making $200-$300 a night in the summer is possible, says Kilian.
Even a tenth of that, which is more of an average day's work, seems to be enough to entice many newcomers to binning, says Francis Taban, who works at the Binners Project and has been a binner himself for 12 years.
"There's more than you can think of," he said.
"It used to be a few guys who had maybe had a drug addiction or maybe [were] alcoholic. Now, it becomes more people losing jobs, less income, cost of living going up."
The rising expenses of everyday life is a reality most Canadians feel all the time, but being a low-income earner is especially difficult right now, says Lars Osberg, a professor of economics at Dalhousie University in Halifax.
People who earn less are more susceptible to job loss during economic downturns. They're more likely to experience wage stagnation or outright lose their jobs, says Osberg.
"We have a rise in poverty and a rise in inequality," he said.
Numbers from Statistics Canada back all that up, too.
The gap between the haves and have-nots in Canada has officially never been wider.
In the first quarter of 2025, the gap between Canada's highest and lowest income households reached a record high. The same report underscored how the lowest-income households, defined as the bottom 20 per cent of the income distribution range, had the weakest growth in their wages compared to a year earlier.
Even in 2024, a report found one in three British Columbians didn't make a living wage, according to an analysis of Statistics Canada data by the Canadian Centre for Policy Alternatives and Living Wage for Families B.C.
Osberg says that situation could be turned around with targeted policies like better income supports.
"We actually need a government that pays attention basically to the vast majority of people who aren't rich, who are struggling with the day-to-day cost of living."
Binning is a low-barrier way to make some extra cash, and according to Taban, "afford a little bit of lifestyle."
All a person needs is time and ideally something to carry cans or bottles in, which might be why so many people are taking it up, he says.
It's gotten so popular in parts of Vancouver that getting to the cans and bottles first has become competitive.
"It's like dogfighting. You're challenged by so many people," said Taban.
He figures a person could make about $100 to $120 a week if they put enough hours into looking through bins.
But he stresses it's not easy money. It's really hard work carrying around heavy bags of cans and bottles, often stinking of beer and wine.
It's a tedious job, says Taban, watching Kilian lug a garbage bag with a dozen cans and some wine bottles.
"He hasn't even made $10 yet."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

B2Gold Increases Position in Founders Metals
B2Gold Increases Position in Founders Metals

Yahoo

time4 minutes ago

  • Yahoo

B2Gold Increases Position in Founders Metals

Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Founders Metals Inc. (TSXV: FDR) (OTCQX: FDMIF) (FSE: 9DL0) ("Founders" or the "Company") announces that B2Gold Corp. ("B2Gold") has completed its obligations under the Shareholder Agreement by purchasing 1,170,000 common shares (the "Shares"), as outlined in the Company's November 5, 2024 press release. B2Gold purchased the Shares in the open market to fulfill its agreement and preserve its right to participate in future financings up to a maximum of 9.9% ownership. Together with its prior private placement subscriptions, B2Gold now holds ~6% of Founders' issued and outstanding common shares on a non-diluted basis. Colin Padget, President and CEO, commented: "B2Gold's decision to increase their position demonstrates strong confidence in Founders and the Antino Gold Project. Their continued investment reinforces our shared belief in Antino as a Tier 1 discovery, and we're pleased to have their ongoing support as we work to unlock the project's full potential and realize value for shareholders." About Founders Metals Inc. Founders Metals is a Canadian-based exploration company focused on advancing the Antino Gold Project located in Suriname, South America, in the heart of the Guiana Shield. Antino is 20,000 hectares and has produced over 500,000 ounces of gold from historical surface and alluvial mining to date1. The Company is systematically advancing one of Suriname's most promising gold exploration and development opportunities with drill-confirmed, district-scale potential. Founders is committed to responsible exploration, community engagement, and delivering long-term value to shareholders through technical excellence and strategic growth in the Guiana Shield. ON BEHALF OF THE BOARD OF DIRECTORS, Per: "Colin Padget" Colin PadgetPresident, Chief Executive Officer, and Director Contact Information Katie MacKenzie, Vice President, Corporate DevelopmentTel: 306 537 8903 | katiem@ Harp Gosal, Director, Investor RelationsTel: 236 301 4211 | harpg@ Cautionary Statement Regarding Forward-Looking Information This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, including statements regarding the use of proceeds from the Company's recently completed financings and the Company's prospects. Forward-looking information can generally be identified by words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or variations indicating that certain actions, events or results "may", "could", "would", "might" or "will" occur or be achieved. Forward-looking statements are based on management's current expectations and reasonable assumptions but are subject to business, market, and economic risks, uncertainties, and contingencies that may cause actual results to differ materially from those expressed or implied, including: general business and economic uncertainties; exploration results; mining industry risks; and other factors described in the Company's most recent annual management discussion and analysis. Although the Company has attempted to identify important factors that could cause actual results to differ materially, other factors may cause results not to be as anticipated. There can be no assurance that forward-looking information will prove accurate, as actual results and future events could differ materially from those anticipated. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information except in accordance with applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. All material information on Founders Metals can be found at 12022 Technical Report - Antino Project; Suriname, South America. K. Raffle, BSc, P. Geo & Rock Lefrançois, BSc, To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Hemostemix's Social Media for Investors and Florida's No-Option Patients
Hemostemix's Social Media for Investors and Florida's No-Option Patients

Yahoo

time4 minutes ago

  • Yahoo

Hemostemix's Social Media for Investors and Florida's No-Option Patients

Calgary, Alberta--(Newsfile Corp. - August 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to its investor awareness and social media strategies and programs. The investor outreach campaign includes: Opt-in SMS alerts to keep existing and prospective investors updated on corporate milestones - text 905-580-4170 to opt-in. Targeted opt-in email provides company news, clinical developments, and financing updates: email: sfarooquoi@ Investor platforms and exchanges ( are designed to increase Hemostemix's visibility, providing due diligence level information that retail and institutional audiences seek about our Company's investment opportunities. "Hemostemix has sold forward $1,143,983 in Therapy Convertible Debenture year-to-date," said Thomas Smeenk, CEO. "Frost and Sullivan awarded our Company the Biotechnology Company of the Year Award, Asia, in 2007, for VesCell™ achievements. Now, with 498 treatments, 11 peer reviewed publications including 7 clinical studies of 318 subjects, including Phase II results that validate our patients' testimonials, we are ramping up sales in Florida, investor outreach, and patient engagement simultaneously. VesCell™ won the World Economic Forum Technology Pioneer Award because it regenerates new circulation in the body where that need is signaled. Next week, I'm down to Florida to meet with cardiologists who have done their homework - stay tuned" Smeenk said. Campaign Strategy & Key Highlights - Testimonials and Publications Storytelling: Real patient testimonials about improved cardiac function, reduction of pain and ulcer healing make the science and treatment relatable and compelling. TIME Magazine highlighted VesCell™ recipient, Bob Grinstead, in Take Heart. Watch six time Grammy award winner and VesCell™ recipient Howie Lindeman. Watch Beefsto's Founder, VesCell™ patient #57, Neim Malo. Platform Utilization: Instagram & Facebook: Hemostemix has shared emotionally driven visuals and success narratives to connect directly with patients, caregivers, and broader communities. LinkedIn: Tailored for professionals and investors—Hemostemix is highlighting our clinical milestones, innovations, and corporate positioning. X: Thomas Smeenk, CEO, @HeartRepairGuy, is providing quick, timely updates, and engagement with practitioners and investor audiences. YouTube: Hemostemix posts its longer-form video content including its weekly webinars and VesCell™ patient testimonials: Results Emphasized in Posts: Cardiac Improvements of up to a 47.1% increase in ejection fraction (LVEF%) in dilated cardiomyopathy patients after one treatment, Schubart et al, Stem Cell Research and Therapy. Phase II CLTI: a 99% reduction in ulcerating wounds size, reduced from a mean of 146 mm² to 0.48 mm² by the end of month three (p=0.01), Henderson et al, JBRES1876. Dual Audience Targeting: The campaign bridges two primary goals: Patient Recruitment: Demonstrating hope, safety, and effectiveness of VesCell™ for no-option CLTI, PAD, and heart patients. Liquidity for Investors: Educating investors and shareholders about the HEM's asymmetrical investment upside, using scientifically validated results and milestones achieved. Summary Table Platform Primary Focus Instagram Visual stories of healing and clinical transformation Facebook Patient-centric storytelling and community engagement LinkedIn Corporate, investor, and scientific communications YouTube In-depth video testimonials and informational content X Brief updates, engagement with the medical & investor audience ABOUT HEMOSTEMIX Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@ / PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Company's social media campaign strategy in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Lowe's buying Foundation Building Materials for about $8.8B as it intensifies focus on pro builders
Lowe's buying Foundation Building Materials for about $8.8B as it intensifies focus on pro builders

Yahoo

time4 minutes ago

  • Yahoo

Lowe's buying Foundation Building Materials for about $8.8B as it intensifies focus on pro builders

Lowe's is buying Foundation Building Materials, a distributor of drywall, insulation and other products, for approximately $8.8 billion as the home improvement retailer intensifies its focus on professional builders. FBM also provides metal framing, ceiling systems, commercial doors and hardware and other products that serve large residential and commercial professionals in both new construction and repair and remodel applications. It has more than 370 locations in the United States and Canada serving 40,000 professional customers. The acquisition is part of Lowe's move to provide more options for professional builders. The Mooresville, North Carolina-based company recently closed on its $1.3 billion acquisition of Artisan Design Group, a provider of design, distribution and installation services for interior surface finishes, including flooring, cabinets and countertops, to home builders and property managers. Rival Home Depot has been making similar moves. In June the home improvement retailer announced that it was buying specialty building products distributor GMS for $4.3 billion. GMS Inc. of Tucker, Georgia, is a distributor of specialty building products like drywall, steel framing and other supplies used in both residential and commercial projects. Home Depot's acquisition of GMS came after it purchased SRS Distribution, a materials provider for professionals, last year for more than $18 billion including debt. SRS provides materials for professionals like roofers, landscapers and pool contractors. Lowe's deal for FBM is expected to close in the fourth quarter. Aside from the acquisition, Lowe's reported its fiscal second-quarter financial results on Wednesday. The company posted an adjusted profit of $4.33 per share, which topped the $4.23 per share that analysts polled by Zacks Investment Research expected. Revenue totaled $23.96 billion in the period, which met Wall Street's expectations. Lowe's raised its full-year sales outlook to a range of $84.5 billion to $85.5 billion. It previous predicted sales would be between $83.5 billion and $84.5 billion for the year. The company's stock rose nearly 3% before the market open.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store